Targeting HIV-specific T cells to the gut for long-lasting HIV remission
Official title: Targeting HIV-specific CAR T cells to the gut for the durable remission of HIV
Funded at University of Minnesota · NIH-11083584 · Data updated 2026-11-12
This study is exploring a new way to help people with HIV by using their own immune cells to find and fight the virus in the gut, with the hope of keeping the virus under control for a long time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $702,446 |
| NIH project number | 5R01DK133907-03 |
| Project ID | NIH-11083584 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who have not achieved viral suppression with standard treatments.
✕Less likely to help
Patients who are not living with HIV or those who have advanced AIDS with significant immune system damage may not benefit from this research.
What this research studies
This research investigates a novel approach to treating HIV by engineering a patient's own T cells to specifically target and attack HIV-infected cells in the gut. The study focuses on understanding how HIV replicates in certain areas of the body, particularly in the intestinal tissues, and aims to enhance the immune response against the virus. By using CAR T cell therapy, which involves modifying T cells to better recognize and eliminate HIV, the researchers hope to achieve a durable remission of the virus. Patients will be monitored to assess the effectiveness of this targeted therapy in reducing viral loads.
Why it matters
Potential benefit: If successful, this research could lead to a long-lasting remission of HIV, reducing the need for ongoing antiretroviral therapy.
How similar studies have gone: Other research has shown promise in using CAR T cell therapy for HIV, indicating potential for success with this targeted approach.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Skinner, Pamela J — University of Minnesota
- Study coordinator: Skinner, Pamela J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.